GSK
GSK plc
There isn't enough reported data to score GSK yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
GSK Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| Unavailable | |
| Healthy |
GSK's profitability and balance sheet are currently healthy. There isn't enough data to rate its revenue and cash flow.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
GSK PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 8.7x | $16.03 | -68% |
| Fair | 14x | $25.09 | -50% |
| Current | 14x | $50.64 | — |
| Expensive | 16x | $29.98 | -41% |
Historical ranges are pointers, not guarantees.
GSK's PE is 14x, but its earnings don't support one, so it isn't a reliable read right now.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH has the edge over GSK in the historical PE scenario, which offers more potential upside but is not a forecast.
GSK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
GSK has the edge over UNH on the outlook, with more favorable revenue expectations.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
GSK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | $1.85 | +123% |
| Q4 2024 | $0.83 | -48% |
| Q4 2023 | $1.59 | -67% |
| Q4 2022 | $4.87 | +238% |
| Q4 2021 | $1.44 | -24% |
| Q4 2020 | $1.90 | +23% |
| Q4 2019 | $1.54 | +27% |
| Q4 2018 | $1.21 | +133% |
GSK has the edge over UNH in the latest year-over-year earnings comparison.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
GSK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $43.5B | +4.1% |
| Q4 2024 | $41.7B | +3.5% |
| Q4 2023 | $40.3B | +3.4% |
| Q4 2022 | $39B | -14% |
| Q4 2021 | $45.4B | 0% |
| Q4 2020 | $45.4B | +1% |
| Q4 2019 | $44.9B | +9.5% |
| Q4 2018 | $41B | +2.1% |
GSK's revenue is shrinking: $43.5B last quarter, down 4.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | 24% | +6.1 points |
| Q4 2024 | 13% | -10 points |
| Q4 2023 | 22% | +1.6 points |
| Q4 2022 | 22% | +4.2 points |
| Q4 2021 | 18% | +4.6 points |
| Q4 2020 | 23% | +15 points |
| Q4 2019 | 21% | +1.7 points |
| Q4 2018 | 18% | N/A |
GSK's operating margin was 24% last quarter, up 6.1 points from the same quarter a year ago, near the top of its range since 2016.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over GSK in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
GSK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | $8.5B | +24% |
| Q4 2024 | $6.9B | -5.5% |
| Q4 2023 | $7.3B | -13% |
| Q4 2022 | $8.3B | -7.7% |
| Q4 2021 | $9B | -6% |
| Q4 2020 | $9.6B | +6.8% |
| Q4 2019 | $9B | -4.5% |
| Q4 2018 | $9.4B | +32% |
GSK's free cash flow has been positive every quarter since mid-2016: $30.9B over the past year, down 16% from the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
GSK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.6% | -25M shares |
| 1 year | +1.6% | +65M shares |
| 3 years | +110% | +2.2B shares |
GSK has 4.1B diluted shares, up 1.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $1.8B |
| Q4 2016 | $5.3M |
| Q3 2016 | $16M |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over GSK on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
GSK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | 1.5x | Healthy |
| Q4 2024 | 2.0x | Moderate |
| Q4 2023 | 1.8x | Healthy |
| Q4 2022 | 2.2x | Moderate |
| Q4 2021 | 2.4x | Moderate |
| Q4 2020 | 2.1x | Moderate |
| Q4 2019 | 3.2x | Elevated |
| Q4 2018 | 3.1x | Elevated |
GSK's net debt is about 1.5 years of its operating earnings (EBITDA), down from 2.4 years a year ago.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
GSK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.6 | Neutral |
| Stochastic | 55.5 | Neutral |
GSK's weekly RSI is 51 (neutral) and its Stochastic is 56 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
GSK PE vs Healthcare Sector
| Metric | GSK | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 26x | 47% below |
| PE % | 53 | 29 | 24 pts above |
GSK has the edge over UNH on valuation relative to its sector.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
GSK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $49.2 | 2.9% above |
| 20 week MA | $50.4 | 0.4% above |
| 50 week MA | $51.9 | 2.4% below |
| 100 week MA | $45.5 | 11% above |
| 200 week MA | $41.7 | 21% above |
GSK's trend is mixed: it's above four of its five weekly moving averages, and 21% above its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 9.3% below its 200-week average.
GSK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $47.3 | $36.1 | -24% |
| 2021 | $36.1 | $43.8 | +21% |
| 2022 | $43.8 | $35.2 | -20% |
| 2023 | $35.2 | $37.1 | +5.2% |
| 2024 | $37.1 | $34.1 | -8% |
| 2025 | $34.1 | $49.1 | +44% |
| 2026 YTD | $49.1 | $50.6 | +3.2% |
GSK has finished lower in three of the last six years. It's up 3.2% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over GSK on returns for 2026, with the stronger performance.